RELMADA THERAPEUTICS, INC. - 10-Q Filing
Relmada Therapeutics reports Q3 2026 cash and short-term investments totaling $202.1M, up from $93.0M at year-end 2025.
Tickers: $RLMD
More Regulatory news
- FACT II Acquisition Corp. - 10-Q Filing
- Marblegate Capital Corp - 10-Q Filing
- Greenland Mines Ltd - 8-K Filing
- InspireMD, Inc. - 8-K Filing
- InspireMD, Inc. - 8-K Filing
- Pinnacle Acquisition Corp - 10-Q Filing
- SUTRO BIOPHARMA, INC. - 8-K Filing
- Aeluma, Inc. - 8-K Filing
- ASTEC INDUSTRIES INC - 8-K Filing
- Live Oak Bancshares, Inc. - 8-K Filing